N
688137
vs
S
Shanghai Composite
Over the past 12 months, Novoprotein Scientific Inc has outperformed Shanghai Composite, delivering a return of +31% compared to the Shanghai Composite's +24% growth.
Stocks Performance
688137 vs Shanghai Composite
Performance Gap
688137 vs Shanghai Composite
Performance By Year
688137 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Novoprotein Scientific Inc
Glance View
Suzhou Novoprotein Scientific Co., Ltd. engages in the research and development, production, and sale of recombinant protein application solutions. The company is headquartered in Suzhou, Jiangsu and currently employs 665 full-time employees. The company went IPO on 2022-09-29. The firm is mainly engaged in the research and development, production and sales of target and factor proteins, recombinant antibodies, enzymes and reagents, and the provision of related technical services. The firm's main products include novel coronavirus diagnostic antibodies, novel coronavirus diagnostic antigens, novel coronavirus pseudoviruses, novel coronavirus non-structural proteins and messenger ribonucleic acid (mRNA) raw materials enzymes and reagents. Its products and services are mainly used in biological medicine, basic research of life science, in vitro diagnosis, mRNA vaccine drugs and other fields. The firm mainly conducts its businesses in domestic and overseas markets.
